
San Fran biotech gets another blow to lead drug; Swiss biotech raises $49 million in Series A — with help from big venture
In the wake of Calithera Biosciences axing a third of its workforce in January over a failed Phase II trial with lead drug telaglenastat in patients with renal cell carcinoma, they just got slammed with the second half of a double whammy.
The South San Francisco biotech announced this morning that it is terminating another Phase II trial involving the drug — this trial had the drug plus standard-of-care chemo being used in patients with NSCLC with either KEAP1 or NFR2 mutations.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters